- Home
- USAS vs YMAB Comparison
USAS vs YMAB Comparison
Compare USAS & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAS
- YMAB
- Stock Information
- Founded
- USAS 1998
- YMAB 2015
- Country
- USAS Canada
- YMAB United States
- Employees
- USAS N/A
- YMAB N/A
- Industry
- USAS Metal Mining
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- USAS Basic Materials
- YMAB Health Care
- Exchange
- USAS Nasdaq
- YMAB Nasdaq
- Market Cap
- USAS 286.7M
- YMAB 270.5M
- IPO Year
- USAS N/A
- YMAB 2018
- Fundamental
- Price
- USAS $0.56
- YMAB $4.95
- Analyst Decision
- USAS Strong Buy
- YMAB Buy
- Analyst Count
- USAS 1
- YMAB 11
- Target Price
- USAS $0.90
- YMAB $19.64
- AVG Volume (30 Days)
- USAS 1.1M
- YMAB 333.1K
- Earning Date
- USAS 05-14-2025
- YMAB 03-04-2025
- Dividend Yield
- USAS N/A
- YMAB N/A
- EPS Growth
- USAS N/A
- YMAB N/A
- EPS
- USAS N/A
- YMAB N/A
- Revenue
- USAS $97,123,000.00
- YMAB $87,685,000.00
- Revenue This Year
- USAS $21.84
- YMAB $20.07
- Revenue Next Year
- USAS $46.00
- YMAB $8.76
- P/E Ratio
- USAS N/A
- YMAB N/A
- Revenue Growth
- USAS 14.33
- YMAB 3.38
- 52 Week Low
- USAS $0.20
- YMAB $4.25
- 52 Week High
- USAS $0.60
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- USAS 58.10
- YMAB 39.96
- Support Level
- USAS $0.45
- YMAB $4.45
- Resistance Level
- USAS $0.59
- YMAB $4.97
- Average True Range (ATR)
- USAS 0.04
- YMAB 0.35
- MACD
- USAS 0.01
- YMAB 0.05
- Stochastic Oscillator
- USAS 80.40
- YMAB 55.45
About USAS Americas Gold and Silver Corporation no par value
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets are The Cosala operations, The Galena Complex, and Relief Canyon. The company also holds interests in the San Felipe Development Project located in Sonora, Mexico. It has geographic focus is the Western Hemisphere, particularly the United States and Mexico.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.